Is cell-free fetal DNA testing a safe option for women in a high-risk population after combined first-trimester testing?

被引:2
作者
Dap, Matthieu [1 ,2 ]
Caffin, Lucie [1 ]
Perdriolle-Galet, Estelle [1 ]
Bonnet, Celine [3 ]
Morel, Olivier [1 ,4 ]
机构
[1] CHRU Nancy, Obstet & Fetal Med Unit, Nancy, France
[2] CHRU Nancy, Dept Fetopathol & Placental Pathol, Nancy, France
[3] CHRU Nancy, Dept Genet, Vandoeuvre Les Nancy, France
[4] Univ Lorraine, INSERM, Diagnost & Intervent Adapt Imaging, Nancy, France
关键词
Cell-free fetal DNA; Non-invasive prenatal testing; High risk; Combined first trimester screening; Trisomy; 21; PRENATAL-DIAGNOSIS; DOWN-SYNDROME;
D O I
10.1016/j.jogoh.2022.102329
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Objectives: Our study aimed to examine the relevance of cell-free fetal DNA (cfDNA) testing on the screening of chromosomal defects and the issue of pregnancies in patients with a risk over 1:50 after the first-trimester combined test. Methods: This is a retrospective monocentric study. We included all consecutive patients with a singleton pregnancy between January 2015 and December 2020 attending our fetal medicine center because the estimated risk for trisomy 21 after the first-trimester combined screening was over 1:50. The patients could either choose to have invasive testing or cell-free DNA testing. We collected data about the patient, the tests results (cfDNA, karyotype) and the pregnancy outcome (born alive, medical termination, miscarriage or intrauterine fetal death). Results: We included 98 patients with an estimated risk for trisomy 21 over 1:50. We found a total of 14 major chromosomal abnormalities (14/98; 14.3%), of which: thirteen trisomies 21 and one triploidy 69, XXY. A cfDNA testing was chosen by 34 (34/98; 34.7%) patients. Among the pathological results of invasive testing, 5 (5/64; 7.8%) couldn't be targeted by cfDNA testing. Two of them were placental mosaicism, one a triploidy 69, XXY, and two defects inherited from a parent and considered benign. There was no miscarriage linked to an invasive test in the population study. Conclusion: In our monocentric cohort, a third of the patients choose cfDNA in a case of a risk over 1:50 after combined testing. Even if this cohort is too small to draw definitive conclusions, cfDNA could be safe in a high-risk population after combined testing. None of the chromosomal abnormalities found at the karyotype and non-detectable by cfDNA was a loss of information that impacted pregnancy follow-up. Further study could explore the input of Genome-Wide cfDNA and chromosomal micro-array in this population.(c) 2022 Elsevier Masson SAS. All rights reserved.
引用
收藏
页数:5
相关论文
共 24 条
[1]   Procedure-related risk of miscarriage following amniocentesis and chorionic villus sampling: a systematic review and meta-analysis [J].
Akolekar, R. ;
Beta, J. ;
Picciarelli, G. ;
Ogilvie, C. ;
D'Antonio, F. .
ULTRASOUND IN OBSTETRICS & GYNECOLOGY, 2015, 45 (01) :16-26
[2]  
Badeau M., 2017, Cochrane Database of Systematic Reviews, DOI DOI 10.1002/14651858.CD011767.pub2
[3]   Position statement from the Chromosome Abnormality Screening Committee on behalf of the Board of the International Society for Prenatal Diagnosis [J].
Benn, Peter ;
Borrell, Antoni ;
Chiu, Rossa W. K. ;
Cuckle, Howard ;
Dugoff, Lorraine ;
Faas, Brigitte ;
Gross, Susan ;
Huang, Tianhua ;
Johnson, Joann ;
Maymon, Ron ;
Norton, Mary ;
Odibo, Anthony ;
Schielen, Peter ;
Spencer, Kevin ;
Wright, Dave ;
Yaron, Yuval .
PRENATAL DIAGNOSIS, 2015, 35 (08) :725-734
[4]   Ethical challenges in providing noninvasive prenatal diagnosis [J].
Benn, Peter A. ;
Chapman, Audrey R. .
CURRENT OPINION IN OBSTETRICS & GYNECOLOGY, 2010, 22 (02) :128-134
[5]   LOW MATERNAL SERUM LEVELS OF PREGNANCY ASSOCIATED PLASMA PROTEIN-A (PAPP-A) IN THE 1ST TRIMESTER IN ASSOCIATION WITH ABNORMAL FETAL KARYOTYPE [J].
BRAMBATI, B ;
MACINTOSH, MCM ;
TEISNER, B ;
MAGUINESS, S ;
SHRIMANKER, K ;
LANZANI, A ;
BONACCHI, I ;
TULUI, L ;
CHARD, T ;
GRUDZINSKAS, JG .
BRITISH JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 1993, 100 (04) :324-326
[6]   Genome-wide cfDNA screening: clinical laboratory experience with the first 10,000 cases [J].
Ehrich, Mathias ;
Tynan, John ;
Mazloom, Amin ;
Almasri, Eyad ;
McCullough, Ron ;
Boomer, Theresa ;
Grosu, Daniel ;
Chibuk, Jason .
GENETICS IN MEDICINE, 2017, 19 (12) :1332-1337
[7]   Current use of noninvasive prenatal testing in Europe, Australia and the USA: A graphical presentation [J].
Gadsboll, Kasper ;
Petersen, Olav B. ;
Gatinois, Vincent ;
Strange, Heather ;
Jacobsson, Bo ;
Wapner, Ronald ;
Vermeesch, Joris R. ;
Vogel, Ida ;
Shand, Antonia ;
Nowakowska, Beata ;
Peterlin, Borut ;
Machtejeviene, Egle ;
Sethna, Farah ;
Stipoljev, Feodora ;
Szirko, Ferenc ;
Grati, Francesca Romana ;
Minarik, Gabriel ;
Duncombe, Greg ;
Helmer, Hanns ;
Hardardottir, Hildur ;
Lebedev, Igor ;
Dickinson, Jan ;
Melo, Joana B. ;
Edwards, Lindsay ;
Hui, Lisa ;
Srebniak, Malgorzata, I ;
Rodriguez de Alba, Marta ;
Vedmedovska, Natalija ;
Calda, Pavel ;
Celec, Petet ;
Muller, Peter ;
Patsalis, Philippos ;
Popp, Radu ;
Liehr, Thomas ;
Eggebo, Torbjorn Moe ;
Stefanovic, Vedran ;
Velissariou, Voula .
ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA, 2020, 99 (06) :722-730
[8]   Analysis of cell-free DNA in maternal blood in screening for fetal aneuploidies: updated meta-analysis [J].
Gil, M. M. ;
Quezada, M. S. ;
Revello, R. ;
Akolekar, R. ;
Nicolaides, K. H. .
ULTRASOUND IN OBSTETRICS & GYNECOLOGY, 2015, 45 (03) :249-266
[9]  
Haute Autorite de Sante, DEC 2018 0243 DC SCI
[10]   Women's and health professionals' preferences for prenatal tests for Down syndrome: a discrete choice experiment to contrast noninvasive prenatal diagnosis with current invasive tests [J].
Hill, Melissa ;
Fisher, Jane ;
Chitty, Lyn S. ;
Morris, Stephen .
GENETICS IN MEDICINE, 2012, 14 (11) :905-913